WallStreetZenWallStreetZen

NASDAQ: KROS
Keros Therapeutics Inc Stock Ownership - Who owns Keros Therapeutics?

OverviewForecastEarningsDividendOwnership

Insider buying vs selling

Have Keros Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Keith RegnanteChief Financial Officer2023-11-0440,000$45.29
$1.81MSell
Keith RegnanteChief Financial Officer2023-11-0440,000$16.00
$640.00kBuy
Keith RegnanteChief Financial Officer2023-06-091,428$46.46
$66.34kSell
Keith RegnanteChief Financial Officer2023-06-092,579$47.25
$121.86kSell
Keith RegnanteChief Financial Officer2023-06-0915,993$45.03
$720.16kSell
Keith RegnanteChief Financial Officer2023-06-0920,000$16.00
$320.00kBuy
Keith RegnanteChief Financial Officer2023-06-0817,301$47.66
$824.57kSell
Keith RegnanteChief Financial Officer2023-06-082,699$48.65
$131.31kSell
Keith RegnanteChief Financial Officer2023-06-0820,000$16.00
$320.00kBuy

1 of 1

KROS insiders have bought as... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KROS insiders and whales buy or sell their stock.

KROS Shareholders

What type of owners hold Keros Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC10.77%3,874,204$224.16MInstitution
Blackrock Inc5.66%2,036,788$117.85MInstitution
Alon Lazarus5.66%2,036,140$117.81MInsider
Arkin Bio Ventures Limited Partnership5.59%2,013,102$116.48MInsider
Alkeon Capital Management LLC4.17%1,498,907$86.73MInstitution
Vanguard Group Inc3.98%1,432,195$82.87MInstitution
Orbimed Advisors LLC3.53%1,268,734$73.41MInstitution
Tomer Kariv3.41%1,226,412$70.96MInsider
Pontifax Management 4 GP 2015 Ltd3.41%1,226,412$70.96MInsider
Ran Nussbaum3.41%1,226,412$70.96MInsider

1 of 3

KROS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KROS70.92%29.08%Net Buying
TGTX53.78%46.22%Net SellingNet Selling
GERN72.04%1.23%Net Buying
KYMR71.48%28.52%Net SellingNet Selling
CLDX82.75%17.25%Net BuyingNet Buying
View Top Biotech Stocks

Keros Therapeutics Stock Ownership FAQ

Who owns Keros Therapeutics?

Keros Therapeutics (NASDAQ: KROS) is owned by 71.51% institutional shareholders, 29.32% Keros Therapeutics insiders, and 0.00% retail investors. Alon Lazarus is the largest individual Keros Therapeutics shareholder, owning 2.04M shares representing 5.66% of the company. Alon Lazarus's Keros Therapeutics shares are currently valued at $117.81M.

If you're new to stock investing, here's how to buy Keros Therapeutics stock.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.